ASX Announcements - Starpharma

ASX Announcements

Jun 2022

Jun 30th, 2022

VIRALEZE™ relaunched by LloydsPharmacy in the UK

Jun 27th, 2022

Starpharma signs expanded DEP® research agreement with US Biopharma Co

Jun 3rd, 2022

Shareholder Newsletter

May 2022

May 27th, 2022

May 27th, 2022

May 18th, 2022

SPL7013 in VIRALEZE™ virucidal against influenza A and B

Apr 2022

Apr 29th, 2022

Quarterly Cashflow and Activities Report

Apr 28th, 2022

Change in Substantial Holder

Apr 27th, 2022

Starpharma to present DEP® at Boston ADC summit

Apr 1st, 2022

Starpharma appoints Dr Jeff Davies and Appendix 3X

Apr 1st, 2022

VIRALEZE™ to relaunch in the UK

Mar 2022

Mar 17th, 2022

Mar 4th, 2022

Response to media article

Mar 1st, 2022

SPL7013 in VIRALEZE™ virucidal against Omicron

Feb 2022

Feb 24th, 2022

Dr Jeff Davies appointed as non-executive director

Feb 21st, 2022

Starpharma Interim Report and Half-Year Financial Results

Feb 4th, 2022

VIRALEZE™ Saudi Arabia Distribution - supplementary information

Feb 4th, 2022

Change in Substantial Holder

Feb 3rd, 2022

VIRALEZE™ sales and distribution in Saudi Arabia and GCC

Feb 1st, 2022

Feb 1st, 2022

Feb 1st, 2022

Jan 2022

Jan 28th, 2022

Quarterly Cashflow and Activities Report

Jan 20th, 2022

Starpharma receives $7.7M R&D tax incentive refund

2022 2021 2020 2019 2018 2017 2016